If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. Chandrika Gowda is a board-certified hematologist/oncologist who has strong commitment to research in childhood cancer, including leukemia and neuroblastoma. Her major research project is to study Role of Ikaros tumor suppressor and pro-oncogenic casein Kinase II(CK2) in leukemogenesis and drug resistance. Dr.Gowda's current work is focused on targeting CK2 for treatment of hematological malignancies.

Her most notable work, published in Blood in 2015, established the novel approach of using specific CK2 inhibitors for treatment of high-risk B cell lineage leukemia using PDX models. She has presented her work at various national and international scientific forums and gained national recognition as an outstanding young investigator.

Dr. Gowda's research is currently supported by several extramural grants. She has also authored several chapters and review articles related to leukemia, CK2 and Ikaros. Her other projects are focused on designing novel therapeutic strategies for treatment of high risk neuroblastoma, which is the most common abdominal solid tumor in young children, with poor prognosis.

Education/Academic qualification

Pediatric Hematology/Oncology, Clinical Fellowship, Penn State Health Milton S. Hershey Medical Center

20102013

Pediatrics, Residency, Monmouth Medical Center

20072010

Fingerprint Dive into the research topics where Chandrika Gowda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 27 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 162 Citations
  • 7 h-Index
  • 4 Article
  • 4 Review article
  • 1 Chapter
  • 1 Letter

Cellular signaling and epigenetic regulation of gene expression in leukemia

Gowda, C., Song, C., Ding, Y., Iyer, S., Dhanyamraju, P. K., McGrath, M., Bamme, Y., Soliman, M., Kane, S., Payne, J. L. & Dovat, S., Jan 2020, In : Advances in Biological Regulation. 75, 100665.

Research output: Contribution to journalReview article

Open Access
  • Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity

    Ding, Y., Zhang, B., Payne, J. L., Song, C., Ge, Z., Gowda, C., Iyer, S., Dhanyamraju, P. K., Dorsam, G., Reeves, M. E., Desai, D., Huang, S., Payne, K. J., Yue, F. & Dovat, S., Nov 1 2019, In : Leukemia. 33, 11, p. 2720-2731 12 p.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations

    Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia

    Gowda, C., Soliman, M., Kapadia, M., Ding, Y., Payne, K. & Dovat, S., Aug 2017, In : Advances in Biological Regulation. 65, p. 16-25 10 p.

    Research output: Contribution to journalReview article

  • 14 Scopus citations

    Casein kinase II (CK2) as a therapeutic target for hematological malignancies

    Gowda, C., Sachdev, M., Muthusami, S., Kapadia, M., Petrovic-Dovat, L., Hartman, M., Ding, Y., Song, C., Payne, J. L., Tan, B. H. & Dovat, S., Jan 1 2017, In : Current Pharmaceutical Design. 23, 1, p. 95-107 13 p.

    Research output: Contribution to journalReview article

  • 10 Scopus citations

    Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros

    Gowda, C., Song, C., Kapadia, M., Payne, J. L., Hu, T., Ding, Y. & Dovat, S., Jan 1 2017, In : Advances in Biological Regulation. 63, p. 71-80 10 p.

    Research output: Contribution to journalReview article

  • 17 Scopus citations